Research on the Heterogeneity of Taiwanese Breast Cancer Patients by Next Generation Sequencing (NGS) Tools
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age20+
Sponsorvghtpe user
About this trial
The objectives of this study are:
1. To determine the difference in genetic profiling of subjects with breast cancer recurrence 2. To determine the comprehensive genetic profiling of subjects with late stage breast cancer 3. To determine the potential biomarkers for early detection and prognosis for breast cancer 4. To determine the genetic profiling of immune system in different subtypes of breast cancer
By integrating and analyzing the data generated using the methods of NGS, these information can be used for:
1. Understanding the genetic profiling of different subtypes of breast cancer in Taiwan 2. Assessing the efficacy of different treatments in breast cancer subjects 3. Defining the molecular risk factors and predicting the potential risk of breast cancer recurrence 4. Assessing the immune repertoire and the potential effects of immunotherapy in breast cancer subjects 5. Developing new strategies in treating patients with triple negative or late stage of breast cancer
Eligibility criteria
Qualifiers
Female subjects aged over 20 years old
Subjects had received surgery for primary breast cancer within 3 years prior to screening [i.e. recurrence within 3 years after surgery (mastectomy or BCS)];
Subjects diagnosed with stage IV breast cancer beyond 3 years after surgery (mastectomy or BCS) or who had received or are currently receiving treatments for breast cancer. And subjects with primary tumor FFPE tissues available and pass the RNA quality check.
Eastern Cooperative Oncology Group (ECOG) Performance score ≤ 3
Disqualifiers
Subjects will be excluded if they had primary cancer other than breast cancer within 5 years prior to screening
Trial design
Treatments tested in this trial
- Diagnostic stage or the Clinical outcome
Treatment groups
1,875 Participants
are divided into 3 treatment groupsSponsors and collaborators
vghtpe user
Lead sponsor
Taipei Veterans General Hospital, Taiwan
Sponsor institution
YongLin Healthcare Foundation
Collaborator
Source ClinicalTrials.gov